This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Cervical cancer | |
|---|---|
| Name | Cervical cancer |
| Field | Oncology |
| Symptoms | Abnormal vaginal bleeding, pelvic pain, postcoital bleeding |
| Causes | Persistent infection with high-risk human papillomavirus (HPV) types |
| Risks | Smoking, immunosuppression, early sexual activity |
| Diagnosis | Cervical cytology, HPV testing, colposcopy, biopsy |
| Treatment | Surgery, radiotherapy, chemotherapy, targeted therapy |
| Prognosis | Stage-dependent survival rates |
Cervical cancer is a malignant neoplasm arising from the uterine cervix. It is largely attributable to persistent infection with oncogenic human papillomavirus types and presents a major global public health challenge with disparities between high-income and low-income regions. Management integrates screening, vaccination, surgical oncology, radiation oncology, and medical oncology strategies, drawing on guidance from international organizations.
Cervical cancer has been central to preventive oncology initiatives championed by institutions such as World Health Organization, Centers for Disease Control and Prevention, National Cancer Institute, Pan American Health Organization, and Gavi, the Vaccine Alliance. Landmark developments in the field include the advent of Papanicolaou screening popularized by George Papanicolaou, prophylactic vaccination initiatives influenced by work at Merck & Co. and GlaxoSmithKline, and global policy frameworks discussed at World Health Assembly sessions. Epidemiological transitions monitored by Global Burden of Disease Study and surveillance from agencies like International Agency for Research on Cancer inform national programs in countries such as United States, India, Brazil, South Africa, and China.
Common presenting features are abnormal vaginal bleeding, postcoital bleeding, and pelvic pain, with advanced disease causing leg swelling and urinary symptoms. Clinical evaluation often involves specialists affiliated with centers such as Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center. Symptom recognition campaigns have been promoted by organizations including American Cancer Society, European Society for Medical Oncology, Royal College of Obstetricians and Gynaecologists, UNICEF, and PATH.
Persistent infection with high-risk human papillomavirus (HPV) types—principally HPV-16 and HPV-18—drives malignant transformation, a relationship elucidated through collaborations involving Harvard University, Planned Parenthood Federation of America, Karolinska Institutet, University of Cambridge, and Imperial College London. Cofactors that modify risk include smoking exposure studied in cohorts from Framingham Heart Study and population studies led by Oxford University; HIV-related immunosuppression documented by Joint United Nations Programme on HIV/AIDS; long-term oral contraceptive use examined in trials sponsored by World Health Organization; and socioeconomic determinants addressed by Bill & Melinda Gates Foundation programs.
Progression from HPV infection to high-grade squamous intraepithelial lesions and invasive carcinoma involves E6 and E7 oncoproteins interfering with p53 and retinoblastoma protein pathways, mechanisms researched at laboratories including Cold Spring Harbor Laboratory, Salk Institute, Broad Institute, National Institutes of Health, and Cambridge University Hospitals. Histologic subtypes—squamous cell carcinoma and adenocarcinoma—have been characterized in studies at Johns Hopkins School of Medicine, King's College London, University of Tokyo, Karolinska University Hospital, and Sheba Medical Center; rarer variants such as adenosquamous carcinoma and small cell neuroendocrine carcinoma are described in tertiary referral centers like Royal Marsden Hospital.
Diagnosis integrates cytology (Pap smear) developed by George Papanicolaou and HPV DNA testing validated in trials conducted by New England Journal of Medicine–published research teams from University of Washington, Columbia University, University of California, San Francisco, Stanford University, and Yale School of Medicine. Confirmatory evaluation uses colposcopy and directed biopsy performed in clinics affiliated with Royal College of Obstetricians and Gynaecologists, American College of Obstetricians and Gynecologists, European Cervical Cancer Screening Network, National Health Service (England), and Canadian Task Force on Preventive Health Care. Imaging for staging employs modalities from vendors and centers such as Siemens Healthineers, GE Healthcare, Magnetic Resonance Imaging, Positron Emission Tomography, and reporting frameworks by American Joint Committee on Cancer.
Primary prevention through prophylactic HPV vaccination using vaccines developed by Merck & Co. (Gardasil) and GlaxoSmithKline (Cervarix) has been implemented in national programs in Australia, Rwanda, United Kingdom, Sweden, and Canada. Screening strategies combining cytology and HPV testing are guided by recommendations from World Health Organization, US Preventive Services Task Force, European Commission expert panels, National Cancer Institute, and country-specific agencies such as Centers for Disease Control and Prevention. Implementation and delivery models have been piloted in partnerships involving PATH, Gavi, the Vaccine Alliance, Bill & Melinda Gates Foundation, Clinton Health Access Initiative, and UNFPA.
Treatment is stage-specific and includes fertility-sparing procedures like conization and radical trachelectomy practiced in centers such as Massachusetts General Hospital, radical hysterectomy developed through contributions at Bergonie Institute, chemoradiation protocols standardized by trials from European Organisation for Research and Treatment of Cancer, Radiation Therapy Oncology Group, and systemic therapies including platinum-based chemotherapy and targeted agents like bevacizumab introduced following trials with sponsors like National Cancer Institute and pharmaceutical companies including Genentech. Multidisciplinary care pathways are coordinated by institutions such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, Vall d'Hebron Institute of Oncology, and comprehensive cancer centers within University of California systems.
Global incidence and mortality estimates provided by World Health Organization and International Agency for Research on Cancer show higher burdens in sub-Saharan Africa, South Asia, and parts of Latin America, affecting countries including Nigeria, India, Kenya, Mozambique, Peru, and Guatemala. Prognosis depends on stage at diagnosis with survival metrics reported in registries such as Surveillance, Epidemiology, and End Results Program, European Cancer Registry, Cancer Registry of Norway, Australian Institute of Health and Welfare, and cohort analyses from Singapore General Hospital. Efforts to eliminate cervical cancer as a public health problem are pursued through initiatives led by World Health Organization, supported by partners such as Gavi, the Vaccine Alliance and Bill & Melinda Gates Foundation.
Category:Gynecological cancer